secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2024-04-29T23:59:59+00:00
Accession:  0001628280-24-018793
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves X4 Pharma's XOLREMDI for WHIM syndrome; pricing set at $496,400/yr
-------------------------------------------------------------------------------

- XOLREMDI (mavorixafor) approved for WHIM syndrome patients aged 12+ to increase neutrophils and lymphocytes.
- Wholesale acquisition cost: $496,400/yr (patients >50 kg, 400 mg daily) and $372,300/yr (≤50 kg, 300 mg daily).
- Launch through specialty pharmacy PANTHERx Rare; X4Connect support program offers copay assistance and insurance help.
- Corporate presentation posted on company website providing business updates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024018793/0001628280-24-018793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024018793/xfor-20240429.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-018793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer